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Introduction 
Neuroactive steroids, or neurosteroids, are 
produced peripherally by exocrine glands, 
such as the ovaries and adrenal glands, and 
can cross the blood-brain barrier to influence 
neuronal signaling [1, 2]. They play important 
roles in the neuroendocrine control of brain 
excitability based on their conversion to 
different metabolites, such as androstenediol 
and estradiol (E2) [3-6].
Even though the brain is only 2% of body 
weight, it contains 25% of the total body 
cholesterol, the main precursor of all hormones 
[7]. Brain cholesterol is involved in myelin sheath 
formation, synaptogenesis, neurotransmission, 
and neurosteroidogenesis [8-13]. Although 
peripherally produced neurosteroids directly 
influence brain functions, it is well-established 
that the nervous system is also a steroidogenic 
tissue and expresses enzymes that are involved 
in the synthesis and metabolism of steroids. This 
unique ability of neurosteroidogenesis allows 
the brain to produce specific steroids required 
for neuroendocrine control and allows the 
brain to protect itself from neurodegeneration 
[14] (Fig. 1). 
Two enzymes come into the foreground 
when discussing neuroprotective activity: 
Aromatase, which converts estrogen from 
androgen during the last step of estrogen 
biosynthesis from cholesterol, and seladin-1, 
which synthesizes cholesterol from desmosterol 
(Table 1). The reason why these two enzymes 
are emphasized in neurodegeneration is 
hidden in the internal dynamics of the brain. It 
is well known that estrogens exert neurotrophic 
and neuroprotective effects by stimulating 
the expression of neurotrophins and cell-
survival factors, enhancing synaptic plasticity, 
and by acting as antioxidants. Estrogens 
are protective under numerous types of 
stressors, including oxidative stress, glutamate 
excitotoxicity, chemical lesions, traumatic or 
mechanical injuries, ischemia, iron toxicity, 
glucose or serum deprivation, and specialized 
disease related pathogens, such as amyloid 
beta (Aβ) and HIV proteins [15]. Aromatase-
mediated estrogen formation in the brain is 
known to have regulatory effects on synaptic 
plasticity, neural stem cell (NSC) proliferation, 
neurogenesis, newborn neuron migration, 
differentiation, survival, and neuroprotection 
[13, 15-23].
The expression of aromatase is regulated 
through the alternative use of multiple, 
promoter-specific first exons (reviewed in [24]). 
These first exons, which remain untranslated, 
are spliced into the coding exons 2 through 10 
of the aromatase gene, resulting in numerous 
aromatase transcripts, all of which code for the 
same protein (reviewed in [24]). Because the 
brain-tissue specific aromatase promoter (I.f ) 
is known, designing a drug to increase local 
estrogen levels in the brain by targeting brain-
specific aromatase transcription is theoretically 
possible [25-27]. 
Therefore, increasing steroid biosynthesis 
specifically in the CNS (central nervous system) 
without affecting peripheral hormone levels 
may be possible by manipulating brain-specific 
promoters of steroidogenic enzymes or by 
post-translationally modifying their protein 
isoforms. Regulation of estrogen synthesis 
in the CNS may be achieved by developing 
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aromatase modulators and can provide new 
approaches for the prevention and therapy of 
the neurodegenerative diseases.
Aromatase and Brain Physiology 
and Pathology: Estrogen-
dependent action
First, the role of aromatase in physiological 
events will be discussed before elaborating on 
its role in brain pathology (Fig. 2). Aromatase 
is the key enzyme catalyzing estrogen 
biosynthesis from androgen precursors, such 
as testosterone. It is mainly a member of 
the cytochrome P450 enzyme family and is 
encoded by the CYP19 gene [28].
Aromatase and its neuroprotective activity 
in the brain were discovered by Naftolin 
in 1976 [29]. Brain aromatase is normally 
synthesized in nerve cells and regulates 
neuronal differentiation, neural, and synaptic 
activity and plasticity, neurogenesis, memory, 
and cognitive functions by producing estrogen 
locally [13, 14, 16, 17, 20-23].
When the aromatase gene was examined 
in detail, researchers discovered that it was 
encoded by different promoters in different 
tissues (reviewed in [24]). In vertebrate 
brains, aromatase is synthesized primarily 
through promoter I.f in the hypothalamus, 
hippocampus, and amygdala [27]. 
Studies conducted to understand the 
physiological significance of aromatase 
showed that aromatase knock-out (ArKO) 
male mice demonstrated aggressive behavior 
patterns [30], while depressive symptoms were 
observed in ArKO female rats [31] and women 
carrying the CYP19 polymorphism [32]. The 
chronic use of aromatase inhibitors in women 
with breast cancer causes damage to visual and 
spatial memory [33, 34]. Aromatase inhibition 
in CA1 pyramidal hippocampal neurons or in 
vitro siRNA silencing of aromatase in neuronal 
cultures results in decreased numbers of 
dendrites and synapses that cannot be restored 
by exogenous estrogen therapy. ArKO rats 
are more susceptible to excitotoxic damage 
compared to normal rats after chronic systemic 
or intracerebroventricular aromatase inhibitor 
administration [35-38].
While neuronal aromatase predominates 
in physiological events, astrocytic aromatase 
participates in pathological conditions [39-43]. 
Indeed, glial aromatase expression increases 
in the early stages of neurodegenerative 
damage and triggers protective local estrogen 
synthesis. The neuronal aromatase that is 
predominant during physiological conditions is 
replaced by glial aromatase, especially around 
damaged neurons. While neurons continue 
Table 1. Comparison of aromatase and seladin-1.
ENZYME
Aromatase
(Estrogen synthase)
Seladin-1
(Selective Alzheimer’s Disease Indicator-1; 
3-beta-hydroxysterol delta-24-reductase)
GENE
CYP19A1
Brain specific promoter I.f DHCR24
LOCALIZATION
Cytoplasmic and presynaptic
Over granulosa cells, testis, adipose tissue,
Placenta,
Subcutaneous fat tissue,
Liver,
Muscle,
Normal breast tissue,
Cancer breast tissue,
Brain
Endoplasmic reticulum and Golgi
Adrenals,
Pituitary,
Thyroids,
Ovaries,
Testis,
Prostate,
Liver,
Lungs
Brain
FUNCTION
Androgen → Estrogen
Normally synthesized in the nerve cells and regulates 
neuronal differentiation, neural and synaptic activity 
and plasticity, neurogenesis, memory and cognitive 
functions by producing local estrogen.
Its expression increased as an acute response to 
neurodegenerative damage.
Its expression decreased in Alzheimer’s Disease.
Desmosterol → Cholesterol
Normally synthesized in the nerve cells, provides 
membrane barrier structure and protects neurons 
from apoptotic cell death by inhibiting caspase-3 
activity, Aβ toxicity and oxidative stress.
Its expression increased as an acute response to 
neurodegenerative damage.
Its expression decreased in Alzheimer’s Disease.
Figure 1. Neuroendocrine and neurosteroidogenic functions of the brain. The brain contains 25% of the total 
body cholesterol, the main precursor of all hormones [7] and has unique ability of neurosteroidogenesis, which 
allows the brain to produce specific steroids required for neuroendocrine control and to protect itself from neu-
rodegeneration. 
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to produce aromatase, glial cells begin to 
produce de novo aromatase synthesis around 
the damage site [18, 23, 41]. Neurotoxic and 
mechanical lesions, head trauma, ischemic 
insults, such as middle cerebral artery occlusion 
(MCAO), and global brain ischemia result in de 
novo enzyme expression in reactive astrocytes. 
Increased aromatase expression in astrocytes 
after brain injury is followed by a significant 
increase in enzymatic activity and increased 
levels of E2 and estrogen receptor-alpha (ERα) 
in the brain. Therefore, it can be said that 
aromatase-mediated estrogen conversion 
from steroid precursors is an endogenous 
defense mechanism of the brain against 
neurodegeneration [41, 43-46]. 
Adult neurogenesis (Fig. 2) involves 
aromatase activity and has been studied 
extensively in zebra finch [47-51] and zebrafish 
(teleofish) brains [52-57]. In mammals, radial 
glial cells (RGCs) behave as neural stem cells 
during embryonic development and transform 
into astrocytes at the perinatal stage [48-50]. 
In fish, they persist during adulthood and 
maintain neural progenitor properties [52-
57]. When a hippocampal lesion is formed, 
astrocytes express aromatase and produces 
estrogen, which then acts as a messenger 
and allows astrocytes to communicate 
with the RGCs. RGCs are progenitor cells 
that express aromatase and are located in 
the subventricular zone around the brain 
ventricles. Studies observed that RGCs migrate 
to damaged sites in the brain and accumulate 
around lesions. Treatment of these cells with 
an aromatase inhibitor, letrozole, or silencing 
of the cholesterol carrier steroidogenic acute 
regulatory protein (StAR) with siRNA has 
been shown to decrease the number of RGCs 
and induce apoptotic cell death. This data 
confirms that aromatase expression and local 
estrogen production regulate hippocampal 
neurogenesis [58-60].
It is well-known that Aβ accumulates in 
AD brains. In hippocampal neurons, estrogen 
has been shown to protect neuronal cells 
from Aβ-mediated cell death by decreasing 
Aβ production and increasing Aβ clearance 
(as reviewed in [61]). Additionally, E2 reduces 
Aβ-induced calcium elevation (Ca2+) in 
hippocampal neurons [62] and prevents 
the hyperphosphorylation of tau, another 
pathological hallmark of AD (as reviewed in 
[63]). Importantly, brains of late-stage AD 
patients have significantly reduced aromatase 
expression, particularly in vulnerable brain 
regions that are also deprived of estrogen 
protection [64, 65]. However, clinical trials 
using hormone replacement therapy (HRT) and 
selective estrogen receptor modulators (SERM) 
to mimic the neuronal protective activity of 
estrogen in AD patients were unsuccessful 
and were abandoned due to the side effects. 
Factors, such as age, basal cognitive activity, 
genetic background of the patients, disease 
stage, and duration of treatment were different 
among patients and likely contributed to 
the failure of HRT and SERM treatment [23, 
63-65]. When the reasons of this failure were 
studied at the cellular level, local estrogens and 
aromatase were also found to be responsible 
[66]. Studies in hippocampal brain slices have 
revealed that local concentration of estrogen is 
six times higher than serum concentration [67]. 
Neuronal estrogen receptor (ER) expression 
Figure 2. Aromatase in brain physiology and pathology. Brain aromatase is normally synthesized in nerve cells and regulates neuronal differentiation, neural and synaptic 
activity and plasticity, neurogenesis, memory, and cognitive functions by producing estrogen locally [13, 14, 16, 17, 20-23]. Aromatase knock-out (ArKO) male mice dem-
onstrated aggressive behavior patterns [30], while depressive symptoms were observed in ArKO female rats [31] and women carrying the CYP19 polymorphism [32]. The 
chronic use of aromatase inhibitors in women with breast cancer causes damage to visual and spatial memory [33, 34]. Glial aromatase expression increases in the early 
stages of neurodegenerative damage and triggers protective local estrogen synthesis [18, 23, 41]. Neurotoxic and mechanical lesions, head trauma, ischemic insults, such 
as middle cerebral artery occlusion (MCAO), and global brain ischemia result in de novo enzyme expression in reactive astrocytes. Aromatase expression and local estrogen 
production also regulate hippocampal neurogenesis [58-60].
Translational Neuroscience
267
is known to be mediated by local estrogen 
synthesis, and neuronal estrogen can only be 
provided by local aromatase activity. When 
local aromatase expression and, therefore, 
local estrogen synthesis is inhibited, neuronal 
ER expression and the protective effect of 
estrogen disappear, regardless of how much 
estrogen is given exogenously [67].
These reports suggest that estrogen can only 
be neuroprotective if sufficient estrogen levels 
are present in the brain before morphological 
changes, such as Aβ plaque formation, occur 
in AD. Therefore, estrogen treatment could 
prevent or slow down the development of AD. 
Once the brain has been deprived of estrogen 
for an extended time, the protective effect 
no longer occurs, and subsequent hormone 
treatment might even be detrimental to 
cognition [66, 67].
Seladin-1 and Brain Physiology and 
Pathology
Studies to investigate the causes of AD have 
resulted in the discovery of a new protein 
approximately 20 years ago by Greeve [68] 
using a differential mRNA display approach. 
This approach identified a novel gene, named 
seladin-1, the abbreviation for Selective 
Alzheimer’s Disease indicator-1, which 
was differentially expressed in selective 
vulnerable brain regions of AD patients, 
such as the hippocampus, amygdala, inferior 
temporal cortex, and the entorhinal cortex. 
Down-regulation of seladin-1 expression 
in these areas was paralleled by increased 
hyperphosphorylated tau, a protein 
component of neurofibrillary tangles, and 
neurodegeneration [68-72].
A later study showed that this protein 
is actually a well-known enzyme, 3-beta-
hydroxysterole delta-24-reductase, that 
is encoded by the DHCR24 gene and was 
identified as a human homolog of the 
DIMINUTO/DWARF1 gene described previously 
in plants [73]. Seladin-1/DHCR24 is highly 
conserved and expressed in the CNS, especially 
in neurons under basal conditions [70]. It 
catalyzes the last step in the biosynthesis 
of cholesterol from desmosterol [74]. The 
deficiency of seladin-1/DHCR24 has been 
shown to decrease cholesterol levels in the 
plasma membrane and subsequently, reduce 
the formation and stability of lipid rafts [75]. 
Thus, as lipid rafts are important for mediating 
cell function [76] downstream cellular signaling 
is also affected [68]. Seladin-1/DHCR24 has 
also been reported to play a role in cellular 
responses against oxidative and oncogenic 
stress and inflammation [77-82]. Independent 
from its enzymatic activity, seladin-1 protein 
has been shown to protect neurons exposed 
to Aβ and oxidative stress from apoptotic 
cell death [70] and inhibit caspase-3 activity 
responsible for apoptosis [83].
Recently, the interactions between 
seladin-1 and estrogen were investigated. 
Fetal neuroepithelial cell (FNC) cultures were 
used to study the relationship between 
seladin-1 and estrogen. These cells synthesize 
ERα and β, as well as seladin-1. An increase in 
seladin-1 mRNA was observed in these cells 
after treatment with 17β-E2 and the SERM, 
tamoxifen. Again, a significant increase in 
seladin-1 expression was detected after FNC 
treatment with a selective ERα agonist. These 
investigators also questioned whether there 
is an estrogen response element (ERE) on the 
seladin-1 gene and they identified a possible 
binding site on the seladin-1 promoter. ERα 
and the seladin-1 promoter was co-transfected 
to these cells. Treatment of the cells with 17β-
E2 and SERM resulted in seladin-1 luciferase 
activity proved that seladin-1 gene has ERE. 
These studies also indicated that seladin-1 is a 
downstream mediator of the neuroprotective 
activity of estrogen [69]. 
In our study, the aromatase inhibitor, 
letrozole, increased seladin-1 protein levels 
significantly in human neuroblastoma cells (SH-
SY5Y). It is known that a decrease in brain E2 
levels is perceived as stress by neurons, and that 
brain aromatase levels increase as a protective/
compensatory mechanism [19]. For this 
reason, we hypothesized that after aromatase 
inhibition, seladin-1 levels are also increased as 
a protective mechanism to compensate for the 
decline in E2 synthesis. To test this hypothesis, 
we measured the E2 level in SH-SY5Y cells and 
observed that it was significantly decreased in 
the letrozole-treated group. Thus, increased 
seladin-1 can trigger an incremental change in 
cholesterol, the precursor for E2 synthesis [84] 
(Fig. 3).
Seladin-1 is also important in the synthesis 
of cholesterol, which contributes to cell 
membrane structure and barrier properties 
[15, 68, 75, 76]. Studies in rat adrenal gland 
cells (PC12), SH-SY5Y cells, and FNCs show 
that seladin-1 protects membrane integrity, 
which provides resistance to Aβ toxicity [85]. 
When seladin-1 is silenced, the integrity of 
the membrane is disturbed, resulting in the 
formation of Ca2+-permeable pores on the 
membrane and subsequent cytotoxicity 
due to Ca2+ hyperexcitation [85]. Seladin-1 
overexpression has been shown to prevent 
this damage by preserving membrane integrity 
[15, 68, 75, 76]. When seladin-1 is knocked out, 
the integrity of the membrane deteriorates, 
making easier for β-secretases (BACE) to break 
down amyloid precursor protein (APP) into Aβ, 
thereby inhibiting plasmin, the enzyme that 
degrades Abs, and causing Aβ accumulation 
[15, 68, 75, 76]. 
In seladin-1 knock-out (SelKO) mouse 
models, homozygous mice were found to be 
born with severe dermopathies and die shortly 
after birth, so experiments are performed using 
heterozygous mice. AD mice were crossed with 
SelKO mice (AD/SelKO) in order to mimic the 
decreased expression of seladin-1 in AD; the 
membrane and intracellular cholesterol levels 
were decreased, and desmosterol levels were 
increased in the AD/SelKO mice. Significant 
Ab1-40 and Aβ 1-42 increases were also observed 
in AD/SelKO mice compared to that in the AD 
mice [75].
In individuals with desmosterolosis, 
a rare congenital anomaly in humans, 
there is a significant decrease in seladin-1 
enzyme activity due to gene mutations, and 
serious neurophysiological changes and 
developmental anomalies are seen [86].
Seladin-1 also plays an important role in 
nerve protection, similar to aromatase, via 
its essential enzymatic activity [71, 72]. It is 
not a coincidence that expression of both 
aromatase and seladin-1 enzymes, especially 
in brain regions sensitive to AD, are found to 
be reduced. Another common feature of these 
enzymes is an increase in their expression 
as an acute response to neurodegenerative 
injury. 
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Brain aromatase and seladin-1 
expression and interactions in AD
AD, the major cause of dementia, is a 
progressive neurodegenerative disorder that 
is characterized by memory loss and cognitive 
deficits with both genetic and environmental 
components [23, 70, 87]. Reduced serum 
estrogen in postmenopausal women has been 
widely reported to increase the risk of AD and is 
correlated with AD-related neuropathological 
changes [88-90]. 
The neuroprotective effects of the 
aromatase product E2 are well established in 
preclinical studies [63, 91]. Although in vitro 
research demonstrated the neurotrophic, 
neuroprotective [92, 93], neuroregenerative, 
anti-inflammatory [94, 95], anti-excitotoxic 
[96], and antioxidant [90, 97, 98] effects of 
estrogen, the data obtained from clinical 
studies are conflicting [89, 92, 97, 99-106] in 
neurodegenerative diseases, such as AD. Early 
trials supported the idea that patients with 
AD could benefit from estrogen therapy by 
improving deficits in memory and cognitive 
functions; however, these studies were 
conducted on perimenopausal women or 
healthy postmenopausal women [106]. In 
addition, several trials suggested that estrogen 
therapy can be effective in preventing AD if the 
therapy is implemented at earlier ages [99-106].
It has been shown that estrogen 
therapy, HRT, could protect at least some 
postmenopausal women against cognitive 
impairment, dementia and AD, if the hormone 
treatment commenced soon after menopause; 
a later start of HRT may be detrimental [107-
111]. This would concur with the hypothesis of 
the “healthy cell bias of estrogen action” [112]. 
Another important factor that could define 
subgroups of women for potential estrogen 
therapy is genetic. Polymorphisms related to 
gonadal steroid synthesis and metabolism 
could affect the outcomes of HRT. Therefore it 
is likely that certain variants of the aromatase 
gene may be associated with the risk of AD 
in women. It has also been shown that CYP19 
polymorphisms affect the risk of AD in women. 
Indeed, CYP19 gene variants could potentially 
affect the risk for AD by reducing or increasing 
the conversion of androgens into estrogens, 
resulting in altered protection against neuronal 
injury or neurodegeneration through multiple 
mechanisms [108]. As a result, alterations 
to plasma estrogen levels cannot always 
reflect the changes occurring in the CNS, and, 
despite its protective effect in vitro, exogenous 
estrogen treatment may not have a therapeutic 
effect [19, 99, 108]. Therefore, the protective 
effect of local estrogen may be dominant in 
the brain, rather than plasma estrogen, and the 
importance of local brain aromatase expression 
and activity is emphasized as the source of E2 in 
the brain [18, 42, 89, 106, 109].
In humans, sex differences in the 
development of AD are frequently discussed; 
for example, the prevalence and severity of AD 
and the rate of decline is higher and cognitive 
Figure 3. Schematic of the interaction between aromatase and seladin-1.  Decrease in brain E2 levels is perceived 
as stress by neurons, and brain aromatase levels increase as a protective/compensatory mechanism [19]. After 
aromatase inhibition, seladin-1 levels increased as a protective mechanism to compensate for the decline in E2 
synthesis. Then, E2 binds the estrogen response element (ERE) on the aromatase gene and regulates the aroma-
tase promoter for neuroprotective activity of estrogen [69]. 
Figure 4. Schematic for the increased aromatase in the DG region of male SelKO/AD mice. Aromatase immuno-
reactivity in neurons increased significantly in the dentate gyrus (DG) region of male SelKO/AD mice compared to 
Sel+/AD (control) mice. Thus, we speculated that aromatase levels may increase either to improve neurogenesis in 
the DG or as a result of neurogenesis after seladin-1 gene expression downregulation in AD 
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deterioration is faster and more pronounced 
in women than in men [110, 111]. In general, 
the strong decline of circulating E2 due to 
menopause is assumed to be a major risk factor 
for AD in women [63]. Neuroprotective effects 
of estrogen, an increased risk of dementia after 
menopause, and a 19–29% higher prevalence 
of AD in women compared to men stimulated 
an investigation into the relationship between 
estrogen, the estrogen-synthesizing enzyme 
aromatase, and AD [64, 65, 108, 112, 113].
In 3-month-old female 5XFAD mice, a 
significant decrease was observed in total 
aromatase expression, which was accompanied 
by reduced aromatase protein level in the 
CA1 and CA3 regions. It is possible that the 
increased production of Aβ inhibits aromatase 
expression in the young mice, which, in turn, 
results in the loss of neuroprotection by E2 [91]. 
This finding indicates that the function of brain-
derived aromatase differs between male and 
female animal models as well.
Furthermore, a transgenic mouse model for 
AD (APP23 mice), in which the animals develop 
Aβ plaques and other pathological changes 
observable in the brains of AD patients [114, 
115], was crossbred with aromatase-KO (Ar−/−) 
mice to test the influence of E2 on the formation 
of Aβ plaques. The resulting female progeny, 
which is Ar+/− and therefore E2-haploinsufficient, 
demonstrated faster and more severe Aβ 
plaque formation and less effective Aβ 
clearance than did aromatase-expressing 
APP23 mice [89]. Ovariectomy of APP23 
females, i.e., the elimination of their major 
source of systemic E2, did not mimic the effects 
of genetically-induced aromatase deficiency 
that affected all aromatase-expressing tissues, 
including the brain. These results suggest that 
brain-derived E2, rather than ovary-derived 
E2, counteracts Aβ plaque formation and is, 
therefore, neuroprotective in female mice. 
Surprisingly, compared with APP23/Ar+/+ mice, 
Aβ plaque production is reduced in male 
APP23/Ar+/− mice, suggesting that endogenous 
testosterone may protect against AD in males 
and that the neuroprotective role of brain-
derived E2 may be sex-dependent [116].
Moreover, in order to investigate interactions 
between aromatase and seladin-1, we used 
5XFAD mice crossed with ArKO or SelKO mice. 
Using immunohistochemical analysis, we 
observed that aromatase immunoreactivity 
in neurons increased significantly in the 
dentate gyrus (DG) region of male SelKO/
AD mice compared to Sel+/AD (control) mice. 
Furthermore, we also observed that E2 levels 
increased in this group, whereas a significant 
decrease was observed in the ArKO group. 
Aromatase increases in the DG of 14–16-week-
old SelKO/AD male mice, during the earlier 
stages of AD [84]. In AD, the aromatase level 
may increase at earlier stages as a protective 
mechanism against neurodegeneration. Similar 
results were observed in vitro when serum, 
the cholesterol source, was removed from cell 
culture media [42], and in vivo as a compensatory 
response to acute neurotoxin administration 
[117-119]. It is tempting to assume that an AD-
related increase in aromatase expression, and, 
therefore, a potential increase in E2 synthesis, 
represents a protective reaction of the tissue 
to early stages of the developing disease [91]. 
Furthermore, the alteration of aromatase levels, 
especially in the DG, can be associated with the 
role of the DG in neurogenesis [120]. Thus, we 
speculated that aromatase levels may increase 
either to improve neurogenesis in the DG or as 
a result of neurogenesis after seladin-1 gene 
expression downregulation in AD (Fig. 4). The 
reason why aromatase increase did not occur 
in female SelKO/AD mice was not apparent, 
in contrast to male mice, but may be due to 
the compensatory effect of higher peripheral 
estrogen against decreased brain estrogen 
in these non-ovariectomized young female 
mice. Brains of SelKO/AD male mice may need 
more local aromatase and estrogen expression 
to compensate for less peripheral estrogen, 
caused by the deprivation of the protective 
effects of gonadal estrogen relative to females, 
and the lack of the neuroprotective effects of 
seladin-1. We suggested that the CNS response 
to neurodegeneration is reflected as an 
increase in the local aromatase level. Therefore, 
the aromatase level does not increase in SelKO/
AD female mice because the neuroprotective 
effect of peripheral estrogen compensates for 
the changes in local estrogen expression [84]. 
In women, decreases in gonadal estrogen and 
local aromatase expression may help to explain 
their vulnerability to neurodegenerative 
events and the increase of AD diagnoses 
after menopause. The sex differences found 
in the mouse model are in agreement with 
previous findings, which indicate that the 
neuroprotective role of brain-derived E2 may be 
more important in females than in males [89, 
113, 116], and may help to explain why women 
are more prone to AD than men [91, 110].
Aromatase in stroke
Several studies have shown that AD 
and ischemic brain injury share similar 
neuropathological features, including altered 
APP processing, Aβ accumulation [121-126], 
and increased neuroinflammation [127]. 
Cerebral ischemia or “ischemic stroke” is caused 
by advanced age, hypertension, previous 
history of stroke or a transient ischemic attack, 
cardiac arrest, traumatic brain injury, diabetes, 
cigarette smoking, atrial fibrillation and high 
cholesterol [128], and results in neuronal death 
predominantly in brain regions that are most 
intrinsically vulnerable, such as the CA1 region 
of the hippocampus [129].
Estrogens display neuroprotective 
properties and promote neural regeneration 
after traumatic brain injury and cerebral 
ischemia by decreasing apoptotic signaling, 
neuroinflammation, and oxidative stress and by 
normalizing glutamate concentrations [130]. 
Aromatase expression increases following 
brain trauma, suggesting that aromatase 
plays an important role in neuroprotection 
by increasing local estrogen levels [23]. These 
neuroprotective effects of estrogen during 
brain ischemia have been well-established 
in ovariectomized rodents and result in a 
significant decrease in the lesion size and 
infarct volume [13, 130, 131].
Aromatase plays an important role 
in endogenous E2-mediated protective 
mechanisms and presents a novel target for 
neuroprotective therapy in ischemic pathology 
[19]. Female ArKO mice have significantly 
increased ischemic damage induced by 
reversible MCAO in all areas of the examined 
brain compared to wild-type littermates. 
The same result was observed when E2 
production was pharmacologically inhibited 
by an aromatase inhibitor, fadrozole [19]. 
Aromatase protein increased after MCAO, and 
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studies evaluating the peri-infarct location and 
astrocytic localization implicate the potential 
for aromatase to promote the survival of cells 
in the penumbra after experimental stroke by 
local synthesis of estrogens [41]. Peterson et al. 
(2001) have shown that aromatase mRNA and 
protein are rapidly and locally upregulated in 
RGCs, and that these cells migrate to injury sites 
following neural damage in zebra finch brains. 
These findings suggest that injury-dependent 
upregulation of aromatase may be a conserved 
characteristic of the vertebrate brain and an 
important component of the initial response of 
neural tissue to injury [40]. 
In addition to aromatase expression, 
transcription of the C/EBPβ protein, a well-known 
mediator of injury and inflammatory responses 
in peripheral tissues [132] and potentially, in 
the brain [133, 134], is increased in ischemic 
hippocampi and decreased after treatment with 
the aromatase inhibitor, megestrol acetate. We 
speculate that, because aromatase is a gene 
associated with regeneration, it is likely to be a 
direct transcriptional target of the C/EBP family 
[135]. 
Moreover, altered lipid metabolism is also 
believed to be a key event that contributes 
to CNS injuries, such as stroke [136, 137]. 
SREBP-1 is a transcription factor best known for 
regulating lipid and cholesterol metabolism. 
The active fragment of SREBP is transported to 
the nucleus where it binds to the promoters of 
SREBP target genes, most of which are involved 
in the synthesis and metabolism of lipids [138]. 
A recent study reported that, while the detailed 
mechanisms by which SREBP-1 activation leads 
to neuronal cell death remain to be established, 
the researchers discovered a method to inhibit 
SREBP-1 and, thereby, significantly reduce cell 
death [139]. In addition, another study showed 
that the removal of fetal bovine serum, a source 
of cholesterol, from cell medium results in 
increased astrocytic aromatase expression and 
activity [140]. We also observed an increase 
in aromatase expression when the serum was 
removed from neuronal cell cultures, and Aβ 
inhibited this aromatase induction. It is known 
that Aβ forms lipid micelles in cell culture and, 
therefore, we speculated that these Aβ-lipid 
micelles blocked the transfer of SREBP-1 to 
the active form, produced a false signal that 
prevented aromatase expression, and blocked 
the protective increase of aromatase in stress 
conditions [141]. Moreover, we investigated the 
effects of indinavir, an inhibitor of nuclear SREBP 
localization, on the expression of aromatase in 
rat hippocampi after transient global ischemia. 
Aromatase and nuclear SREBP-1 protein levels 
significantly increased after transient global 
ischemia in the rat hippocampi, and this 
increase was reduced by indinavir treatment 
[141]. Taghibiglou et al. (2009) found that 
SREBP-1 activity increased during oxygen and 
glucose deprivation, conditions that mimic 
ischemic stroke, in neuronal cells, and that this 
activation was blocked by N-methyl-D-aspartate 
receptor (NMDAR) antagonists. One study also 
reported that SREBP-1 was activated in a mouse 
model of ischemic stroke and this activation 
in affected neurons was an essential step for 
NMDAR-mediated excitotoxic neuronal death. 
Inactivation of the SREBP-1 pathway was shown 
to reduce neuronal damage after stroke in mice 
[139]. Moreover, another report suggests that 
the excitatory receptor-dependent activation of 
SREBP-1 promotes neuronal cell death [142]. 
Our conclusions from these studies support 
the central hypothesis that the upregulation 
of aromatase in ischemic hippocampi and its 
downregulation in megestrol acetate-treated 
and indinavir-treated tissues may partly depend 
on transcription factors, such as C/EBPβ [135] 
and SREBP-1 [141], respectively. Our findings 
indicate that ischemia, as well as chronic 
neurodegenerative processes, lead to increased 
cytoplasmic aromatase and nuclear C/EBPβ 
and SREBP-1. Thus, it is possible to hypothesize 
an interaction between this enzyme and 
transcription factors [135, 141]. 
Interestingly, clinical and experimental 
findings after stroke are abundant and highlight 
important sex differences [143, 144]. Clinical 
studies showed that aging women display worse 
outcomes following an ischemic stroke than 
men, and that women also have higher mortality 
after hemorrhagic strokes [145]. In addition, 
rodents ischemic stroke models demonstrate 
that young females have smaller infarcted area 
than young males [146] and that they exhibit 
less severe stroke consequences during pro-
estrus (high 17β-E2 concentration) than during 
metestrus (low 17β-E2 concentration) [147]. 
During aging, mortality is higher in females than 
in males, and males display greater bleeding 
and mortality during hemorrhagic strokes [145]. 
The study also showed that estrogen treatments 
improve outcomes in young females and 
males after ischemic and hemorrhagic strokes, 
although their effects in aging females during 
ischemia are controversial [145]. Other clinical 
and experimental findings also document the 
impact of sex and sex steroids in other CNS 
insults [148, 149]. 
Seladin-1 in Stroke
A previous study showed that APP and Aβ, or 
their fragments, aggregate in dense plaque-
like deposits in the thalamus of rats subjected 
to transient MCAO [150]. Subsequently, it was 
demonstrated that APP processing and the 
expression of Aβ-degrading enzymes are altered 
in the ipsilateral thalamus following MCAO, 
and that this damage remains long after the 
initial ischemic insult [151]. These alterations 
coincided with significantly augmented Ca+2 
levels, depletion of BACE trafficking proteins 
and increased BACE activity in the ipsilateral 
thalamus. Based on these findings, the observed 
alterations resulting in Aβ accumulation could 
be linked to disrupted Ca+2 homeostasis. A non-
selective Ca+2 channel blocker, bepridil, inhibits 
BACE-mediated APP cleavage in vitro and in vivo 
[152-154] and significantly decreased Ca+2 levels 
[155]. This decrease was strongly correlated with 
reduced Aβ42 and Aβ40 levels in the ipsilateral 
thalamus of MCAO rats. Seladin-1 decreased 
at both mRNA and protein levels after MCAO; 
conversely, bepridil treatment restored seladin-1 
expression in the ipsilateral thalamus of MCAO 
rats and was associated with the improved 
neuronal survival [156]. The seladin-1 protein is 
encoded by the DHCR24 gene and is a potential 
neuroprotective factor. This notion stems from 
previous studies, which showed that seladin-1 
plays a cytoprotective role in oxidative stress-
induced apoptosis by scavenging reactive 
oxygen species [83]. Moreover, seladin-1 
interacts with the p53 tumor suppressor protein 
[77], a redox-sensitive transcription factor 
involved in the pathogenesis of brain ischemia 
and AD. Importantly, seladin-1 expression is 
downregulated in large pyramidal neurons in 
specific regions in AD brain and suggests that 
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seladin-1 is associated with selective neuronal 
vulnerability [68-72]. 
From this evidence, it seems reasonable to 
speculate that neuronal damage accompanied 
by a reduction in seladin-1, similar to reports 
in certain AD brains, will have important 
consequences in the CNS response to ischemia. 
Thus, paucity in seladin-1 could affect the 
amount of damage and time of recovery from 
ischemia, as it is highly dependent on the 
amount of stress to the affected area [82].
Recently, Sel+/− and wild-type (WT) mice 
were subjected to permanent MCAO. Sel+/− 
mice displayed larger infarct volumes after 
MCAO than their WT littermates. Moreover, 
treatment of WT mice with the seladin-1 
inhibitor, U18666A, increased ischemic lesions. 
Inflammation related mediators, such as COX-
2, iNOS, TNF-α, and IL-10, were increased after 
ischemia in Sel+/− mice, compared with WT 
counterparts [82].
Brain aromatase and seladin-1 in 
epilepsy. 
Epilepsy is the most common serious 
neurological disease and is defined as “a disease 
of the brain characterized by an enduring 
predisposition to generate epileptic seizures” 
[157]. Epilepsy, antiepileptic drugs (AEDs), 
and the reproductive system exhibit complex 
mechanisms of action. Reproductive endocrine 
and sexual dysfunction are more common in 
patients with partial epilepsy than in those with 
generalized epilepsy [157-167], particularly 
in temporal lobe epilepsy that affects the 
limbic system, because this area is extensively 
interconnected with the hypothalamic nuclei 
that regulate gonadal function [168-170]. This 
region controls gonadal hormones, including 
estrogen, which is converted from testosterone 
by aromatase. Patients with temporal lobe 
epilepsy have higher aromatase activity in 
the cerebral cortex than in subcortical areas. 
Inhibition of cerebral aromatization results 
in lower focal availability of estrogen and, 
theoretically, improves seizure control [171]. 
While the increase in aromatase expression, 
and, thus, the synthesis of estrogen, in head 
trauma, ischemia and AD are neuroprotective, 
the effects of estrogen on epilepsy are complex. 
A recent study established that estrogens are 
epileptogenic [172] and have proconvulsive 
effects [173]. This effect is due to the ability 
of estrogens to lower the seizure threshold, 
thereby increase seizure discharges [172, 174], 
and to increase neural membrane excitability 
[173, 175]. However, there have also been some 
studies that hint at a potential anticonvulsant 
role of estrogen [175], highlighting not only the 
complex role of gonadal hormones in the body 
but also the complex etiology of epilepsy itself. 
Thus, E2 has mixed effects, ranging from no effect, 
mild anticonvulsant to proconvulsant effects, on 
seizures that depend on whether physiological 
or supraphysiological doses have been used 
[176]. In that sense, aromatase enzyme 
inhibitors may have great potential for use as 
an antiepileptic treatment [177]. In some clinical 
trials, aromatase inhibitors have been used to 
treat prostate hypertrophy; some success was 
reported in men with complex partial epilepsy 
treated using this drug and other aromatase 
inhibitors [178-180]. In fact, letrozole, approved 
for the treatment of breast cancer by the Food 
and Drug Administration (FDA) [181], has been 
clinically successful in treating epilepsy in men 
[178]. In a case study, a 61-year-old man with 
temporal lobe epilepsy and sexual dysfunction 
due to low testosterone levels used letrozole to 
normalize his testosterone level and improve 
his sexual function and seizure control [178, 
180]. Therefore, testosterone supplementation, 
concomitant aromatase inhibitors [182], and 
AEDs with aromatase-inhibiting properties 
should be further investigated as a beneficial 
treatment for male patients with epilepsy [161-
163, 177, 178, 185-187]. 
Therefore, twelve AEDs were tested on 
commercially available microsomes, from 
transfected insect cells, for their ability to 
inhibit aromatase using dibenzylfluorescein 
as a substrate. The drugs inhibiting aromatase 
were: lamotrigine, oxcarbazepine, tiagabine, 
phenobarbital, phenytoin, ethosuximide, and 
valproate. Gabapentin, primidone, topiramate, 
and vigabatrin showed no inhibition [177]. Most 
therapies, apart from inhibiting aromatase, 
are based on estrogen-lowering drugs and 
act via various mechanisms, such as linking 
estrogens to globulins (carbamazepine) [158], 
binding to estrogen receptors (neurontin and 
gabapentine–2-[1-(aminomethyl)cyclohexyl]
acetic acid), or by inhibiting steroid sulfatase 
activity (topiramate-sulphamate). These studies 
suggest that the molecular mechanisms of 
AEDs are related to either steroid binding or 
synthesis. Enzyme-inducing AEDs, such as 
phenobarbital, phenytoin, and carbamazepine, 
can directly suppress gonadal testosterone 
synthesis [186], increase hepatic synthesis of 
sex hormone-binding globulin (SHBG) [187], 
and increase serum E2 levels, either in absolute 
concentrations or relative to bioavailable 
testosterone (BAT), and are associated with 
hyposexuality and hypogonadism [188, 189]. 
Therefore, a small increase in E2 level, presumably 
as a result of an AED-induced aromatase activity 
increase, could have a disproportionately large 
negative feedback effect and contribute to 
hypogonadism [190]. 
The effects of AEDs on aromatase and the 
expression level of its coding gene CYP19 were 
examined in the liver, but not in the brain or 
gonads [191]. Therefore, we investigated the 
possible effects of the highly efficient, new-
generation, antiseizure/anticonvulsant drug, 
levetiracetam (LEV), on central and gonadal 
aromatase expression and gonadal tissue 
functionality. Epileptogenesis was generated in 
male Wistar rats by an intraperitoneal injection of 
the excitotoxic agent kainic acid (KA). Significant 
decrease in the average spike number, amplitude, 
and frequency by electroencephalography (EEG) 
were observed in KA-treated rats that received 
an extrapolated dose (27 mg/kg/day) of LEV 
from a clinically used human dose (1000 mg/75 
kg adult) at all time points when compared to 
the first day of the experiment. LEV did not affect 
seladin-1 expression levels in the brains of male 
rats, suggesting that increases in KA-induced 
neurosteroidogenic enzyme expression were 
specific to aromatase. Our study indicates that 
LEV exerts a slight inhibitory effect on basal 
central aromatase and attenuates testicular 
aromatase [185]. These results also correlate 
with a significant downregulation of CYP19 in 
H295R cells exposed to LEV at intermediate 
(100 μM) and high (175 μM) concentrations in 
vitro [192]. LEV decreases aromatase levels in 
the testis and increases the seizure threshold, 
possibly by decreasing systemic E2 levels. LEV 
does not induce testicular aromatase, affect 
the contractility function of the vas deferens, or 
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induce significant changes to the histology of 
male gonadal tissues. Therefore, these may partly 
explain why LEV does not cause reproductive 
dysfunction. LEV may produce a central 
alteration in the testosterone/estrogen ratio by 
decreasing the expression of brain and gonadal 
aromatase. Furthermore, we suggest that the 
effects of the antiseizure drugs on central and 
testicular aromatase may be investigated to 
determine if they may be beneficial for treating 
male patients with epilepsy [185]. 
It has also been suggested that E2 enhances 
neuronal excitability in the hippocampi of male 
but not female rats [176]. However, contrary 
to these conclusions, AEDs and epilepsy are 
often associated with sexual disorders in 
women as well, such as in hyperandrogenism, 
menstrual disorders, and ovarian cysts. 
Patients with epilepsy often show hormonal 
abnormalities, which may be caused either 
by epilepsy or by continuous treatment with 
AEDs [158]. Among women, the relationship 
between epilepsy and estrogen imbalance is 
especially striking. For example, it has been 
shown that approximately 56.5% of women 
with amenorrhea or anovulatory cycles have 
EEG abnormalities [172]. Seizure frequency 
can also be associated with perimenarche, 
menarche [172, 173], menstruation [172-174, 
193], pregnancy [172, 173], perimenopause 
[172-174, 193], and menopause [172-174, 
193]. Catamenial epilepsy, a form of epilepsy in 
which the periodicity of seizure exacerbation 
corresponds closely with the menstrual cycle, 
is thought to affect between 30% to 70% of 
epileptic females [172-174, 193]. However, the 
periodicity of seizures is common among both 
sexes [174, 177].
The use of aminoglutethimide, a first-
generation aromatase inhibitor, has been 
attempted as an antiepileptic drug in 
combination with other standard drugs [194]. 
Letrozole is a third-generation, reversible, 
nonsteroidal aromatase inhibitor, that 
was approved by FDA for the treatment of 
postmenopausal women with hormone 
receptor-positive or hormone receptor-
unknown locally advanced and metastatic 
breast cancer [195]. A recent preclinical 
study demonstrated the protective effect 
of letrozole in preventing kindling induced 
a number of antiepileptic compounds with a 
high potential for aromatase inhibition [177].
Conclusion
The identification of the brain-specific aromatase 
promoter and the activity of local estrogen 
through ERα and its downstream regulator, 
seladin-1, propose these enzymes to be new 
targets in drug design for the treatment of 
neurodegenerative diseases, such as AD, stroke, 
and epilepsy.
Thus, therapeutic approaches that enhance 
aromatase activity may be targeted to promote 
neuroprotection in neurodegenerative 
diseases. Furthermore, systemic delivery of 
steroidal hormones, such as estrogen, for their 
neuroprotective effects have some potential 
risks, such as breast and ovarian cancer. 
Therapeutic approaches that are alternative to 
systemic steroid administration will highlight 
the neuroprotective effects of these steroids and 
will be advantageous in neuroprotection. 
In conclusion, centrally produced gonadal 
steroids exert numerous actions, including 
neuroprotection, constitutive expression of 
estrogen and regeneration.
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by pentylenetetrazole (PTZ) in mice [196]. 
Moreover, letrozole was previously reported 
to inhibit the testosterone-induced increase 
in PTZ seizure activity in mice [197]. Letrozole 
administration prior to KA significantly 
increased the latency to onset of seizures and 
reduced seizure occurrence in mice. However, 
the drug demonstrated no discernible effects 
on KA-mediated neurotoxicity [6]. 
It is interesting to note that letrozole is 
easily transported across the blood–brain 
barrier after systemic application and exerts 
an inhibitory influence on hippocampal 
estrogen synthesis, as it does in other regions 
of the body in mice [198]. Therefore, it was 
shown that systemic and local inhibition of 
aromatase activity by letrozole causes spine 
synapse loss and significantly impairs (long 
term potentiation) LTP in the hippocampus of 
female and ovariectomized mice, but not in 
male mice. Thus, ovariectomy itself does not 
influence LTP, and all evidence points to a role 
of hippocampus-derived estrogen, rather than 
to a role of estrogen from peripheral sources, 
for the LTP. In this context, it is useful to consider 
that testosterone is also neuroprotective in 
the male brain [199] after letrozole treatment 
since testosterone is the direct substrate of 
aromatase [200].
A case report of a 61-year-old woman with 
long-standing epilepsy, since age 19, with an 
average seizure frequency of 5–8 per month 
(93/year; range 83–142/year) and a diagnosis 
of post-menopausal breast cancer at the age 
of 56, had halved her seizure frequency to an 
average of <4 per month. Replacing tamoxifen 
with exemestane, an aromatase inhibitor, 
resulted in complete abolition of seizures, and 
the patient has remained seizure-free for over 
4 years. This suggests that aromatase inhibitors 
may be beneficial as a mono-therapy or an 
adjuvant for the treatment of epilepsy, and 
further research in this area is warranted [171]. 
Computer-based pharmacophore searches 
using a model based on aromatase inhibition 
and the enzyme’s structural features can be 
used to screen for new candidate antiepileptic 
therapies. In fact, potent aromatase inhibitors 
and current antiepileptic compounds display 
significant (over 70%) chemical and structural 
similarity, and similarity analyses have proposed 
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